AUTL — Autolus Therapeutics plc
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1730463 ·
Last close
$2.34
Market Cap
$622.82M
52W High
$2.58
52W Low
$1.38
ADV30
2,665,735
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 26,218,000 | 1,650,000 | -59,513,000 | -71,598,000 | 527,065,000 | 130,925,000 | 418,239,000 |
| Dec 2025 | 24,289,000 | -1,041,000 | -72,469,000 | -90,332,000 | 589,068,000 | 104,132,000 | 410,939,000 |
| Sep 2025 | 21,194,000 | -7,449,000 | -71,621,000 | -79,118,000 | 661,947,000 | 86,124,000 | 396,495,000 |
| Jun 2025 | 20,923,000 | -3,522,000 | -61,217,000 | -47,917,000 | 720,981,000 | 123,825,000 | 374,517,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-273,320,000
Investing CF
$314,156,000
Financing CF
$-6,401,000
CapEx
$-30,705,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.01
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,458,350,000
Inventory
$33,233,000
Receivables
$86,256,000
ST Investments
$98,509,000
EBIT TTM
$-257,573,000
Pretax Income TTM
$-288,356,000
Interest Exp TTM
$54,623,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,078,500
EBITDA
$-68,942,608
Free Cash Flow
—
Enterprise Value
$-125,332,080
Total Cash
$217,450,000
Total Debt
$0
Shares Out
266,162,540
Trailing EPS
$-1.03
Book Value
$5.91
ROE
-29.6%
ROA
-22.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 75,388,000 | -270,544,000 | -287,528,000 | 589,068,000 | 410,939,000 | — | -283,568,000 |
| Dec 2024 | 10,120,000 | -241,426,000 | -220,662,000 | 782,725,000 | 355,400,000 | — | -206,271,000 |
| Dec 2023 | 1,698,000 | -175,528,000 | -208,383,000 | 375,381,000 | 263,907,000 | — | -145,587,000 |
| Dec 2022 | 6,194,000 | -142,893,000 | -148,839,000 | 490,274,000 | 191,600,000 | — | -112,308,000 |
TTM Snapshot
Revenues TTM
$3,811,000
NetIncome TTM
$-170,710,000
OpCashFlow TTM
$0
Assets (Latest)
$782,725,000
Forward EPS
$-0.63
Max Pain — expiry 2026-12-18
max pain strike: $1.50 · spot: $2.38 · call oi: 3,518 · put oi: 74
Expected Move to 2026-12-18:
±$1.65
(69.32%) —
implied range
$0.73 –
$4.03
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGMB | Agomab Therapeutics NV | $631.36M | $12.82 | — |
| VALN | Valneva SE | $640.06M | $6.75 | — |
| EIKN | Eikon Therapeutics, Inc. | $604.48M | $11.16 | — |
| ZURA | Zura Bio Ltd | $603.72M | $6.30 | — |
| ENTX | Entera Bio Ltd. | $592.15M | $3.42 | — |
News headlines (Yahoo Finance, 1h cache)
Autolus Therapeutics Q2 Earnings Call Highlights
2026-08-11 14:04 · Yahoo
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
2026-08-11 11:00 · Yahoo
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
2026-08-03 20:05 · Yahoo
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
2026-08-03 11:13 · Yahoo
Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees
2026-07-14 10:33 · Yahoo
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01 20:05 · Yahoo
Autolus Therapeutics to Participate in Upcoming Investor Conference
2026-06-25 11:00 · Yahoo
Why Autolus Therapeutics (AUTL) Looks Less Speculative as AUCATZYL Revenue Builds
2026-06-17 15:16 · Yahoo
Autolus Therapeutics Receives Prix Galien UK Award
2026-06-12 08:00 · Yahoo
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2026-06-10 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.